BioReference Laboratories
Opko Health Q1 Revenues More Than Double Due to COVID-19 Test Demand
The company reported revenues of $545.2 million compared to $211.5 million in the year-ago quarter, primarily driven by COVID-19 testing.
BioReference Labs Inks Deal to Provide Rapid PCR, Point-of-Care COVID-19 Testing for MLB
The firm is using Mesa Biotech's Accula system for the testing, beginning Thursday, the start of the 2021 MLB season.
Opko Health Q4 Revenues More Than Double Thanks to COVID-19 Testing
The company's service revenues increased 157 percent to $457.9 million due to significant COVID-19 testing volumes, slightly offset by lower base business volumes.
While SARS-CoV-2 test demand will likely remain strong well into 2021, the question of what to do with the built-up capacity in a post-COVID-19 environment looms.
Opko Health Q3 Revenues Up 87 Percent
The firm's subsidiary BioReference Laboratories performed 3.5 million COVID-19 PCR tests and 300,000 serology tests during the quarter.
Jun 22, 2018
Apr 24, 2017
Diaceutics Inks Deal for BioReference Labs Dx Data
Oct 10, 2016
May 9, 2016